However, the patient reported a severe headache following treatment with oral prednisolone and tacrolimus. Tacrolimus was discontinued, and mycophenolate mofetil was instead administered with a favorable outcome. Mycophenolate mofetil should therefore be considered as an alternative treatment for anti-MDA-5-positive interstitial lung disease in cases where calcineurin inhibitors cannot be used.

P3, N=346, Active, not recruiting, Hospices Civils de Lyon | Recruiting --> Active, not recruiting

Various bile duct imaging findings of immune-related adverse event-sclerosing cholangitis were revealed; transpapillary bile duct biopsy may be useful in the diagnosis of immune-related adverse event-sclerosing cholangitis. Despite the combination of multiple immunosuppressive agents, prognosis of immune-related adverse event-sclerosing cholangitis remains poor. Longer follow-up and larger clinical studies are necessary to establish its treatment strategy.

P1/2, N=54, Not yet recruiting, Eyestem Research Pvt. Ltd.

P1, N=39, Recruiting, Institut National de la Santé Et de la Recherche Médicale, France | Not yet recruiting --> Recruiting

P2, N=40, Not yet recruiting, Sound Pharmaceuticals, Incorporated

P=N/A, N=63, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting

P4, N=116, Terminated, King's College London | Active, not recruiting --> Terminated; Primary endpoint not reached.

P2, N=10, Active, not recruiting, Sidney Kimmel Cancer Center at Thomas Jefferson University | Trial primary completion date: Sep 2023 --> Sep 2024

P1, N=39, Not yet recruiting, Institut National de la Santé Et de la Recherche Médicale, France | Trial completion date: Jun 2027 --> Oct 2027 | Initiation date: Nov 2023 --> Mar 2024 | Trial primary completion date: Jan 2027 --> May 2027

P2/3, N=205, Recruiting, The First Affiliated Hospital of Xiamen University | Not yet recruiting --> Recruiting

P3, N=332, Not yet recruiting, Nantes University Hospital

FAV-INA was safe in RPMI 2650 nasal and SH-SY5Y neuroblastoma cells without any in vitro cytotoxicity observed. This study demonstrated that combining the merits of cocrystallization and particle engineering via SFD can propel the development of advanced dry powder formulations for intranasal drug delivery.

Characterization of T-cell function and proliferation showed higher levels of GranzymeB in HTLV-1+ donors. The improvement and stability of symptoms in this patient with HAM/TSP following MMA initiation requires further study as a potential treatment for HAM/TSP.

P=N/A, N=146, Active, not recruiting, Ajay Israni | Recruiting --> Active, not recruiting | N=250 --> 146

Indeed, this was associated with reduced levels of hTERT and CDK1 and shift in the cell cycle distribution. Our findings suggest that the TAM/FAV combination exhibits synergistic effects against TAMR-1 human breast cancer cells by targeting hTERT.

Our data indicate that the neuroprotective potential of CA, ED, and EB may be revealed in vitro only under specific conditions, with their rather narrow micromolar concentrations, relevant cellular model, type of toxic agent, and exposure time. Nevertheless, of the three compounds tested, CA displayed the most consistent neuroprotective effects.

P2, N=105, Recruiting, Children's Hospital Medical Center, Cincinnati | Not yet recruiting --> Recruiting

P=N/A, N=18, Recruiting, Shanghai Changzheng Hospital

P2, N=38, Completed, City of Hope Medical Center | Active, not recruiting --> Completed

The levels of tGSH (7.58 ± 1.98 vs 2.50 ± 0.98 nmol/ml) and SOD (13.63 ± 3.43 vs 3.81 ± 1.43 U/ml) the FAV200 group were lower than the HG (p < 0.05, for all). The degree of damage to the cornea and sclera of the FAV200 group was quite high according to HG (p < 0.001). Favipiravir can cause damage to rat conjunctiva and sclera by increasing oxidant stress and inflammation at high dose.

P3, N=254, Active, not recruiting, Sound Pharmaceuticals, Incorporated

P=N/A, N=400, Recruiting, Johns Hopkins University | Not yet recruiting --> Recruiting

Immunosuppression consists of a triple drug standard regimen comprising tacrolimus (TAC) and corticosteroids (CS) with either mycophenolate mofetil (MMF) or sirolimus (SIR)/everolimus (EVE)...Drug type and concentration: single drug [EVE, 5 ng/mL; SIR, 5 ng/mL; TAC, 5 ng/mL; cyclosporine A (CSA), 125 ng/mL; MMF, 15 µg/mL; CS, 0.5 µg/mL] and combined immunosuppressants (Group 1: TAC, 5 ng/mL + MMF, 15 µg/mL + CS, 0.5 µg/mL; Group 2: TAC, 5 ng/mL + SIR, 5 ng/mL + CS, 0.5 µg/mL; Group 3: TAC, 5 ng/mL + EVE, 5 ng/mL + CS, 0.5 µg/mL)...The SIR group had stronger NK cell activity compared with that of the MMF group, although liver transplantation patients have lower NK cell activity and function. Despite an overall comparable immunosuppressive efficiency in terms of prevention of acute rejection, a mTORIs-including regimen might be considered as having less impact on NK cell function.

P4, N=130, Active, not recruiting, The University of Hong Kong | Recruiting --> Active, not recruiting | N=200 --> 130 | Trial completion date: Jun 2024 --> Jan 2025 | Trial primary completion date: Jun 2024 --> Jan 2025

P=N/A, N=400, Not yet recruiting, Johns Hopkins University

P=N/A, N=15, Recruiting, Tianjin Medical University | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024

P=N/A, N=400, Not yet recruiting, Johns Hopkins University

Our phase I clinical trial investigates combining mycophenolate mofetil (MMF) and temozolomide (TMZ) to target de novo purine biosynthesis in GBM. We aim to combine this data with analysis of our Phase I clinical samples to retrospectively establish SLC1A5 as a biomarker for MMF/TMZ sensitivity and investigate its role in tumorigenic purine metabolism. Identifying predictive markers will enhance personalized treatment strategies for GBM, offering hope for improved outcomes.

However, previous studies have not demonstrated their efficacy in preventing graft-versus-host disease (GVHD) when combined with the standard GVHD prophylaxis regimen consisting of calcineurin inhibitors and methotrexate...Thirty one pts received conditioning with fludarabine (160 mg/m2) + melphalan (100-140 mg/m2) + TBI (2-4Gy) or thiotepa 5 mg/kg...Among the pts who received treatment for aGVHD, the median cumulative systemic steroid exposure (in prednisone equivalents) was 1,318 mg (IQR 623-3,775) at D+100 and 1,325 mg (IQR 525-1,640) at D+180, with a median treatment duration of 40 days (IQR 25-110)... The addition of budesonide to PTCy-based GVHD prophylaxis regimen (PTCy-TMB) is feasible and appears to be effective in preventing severe GI aGVHD, without compromising transplant outcomes and immunologic reconstitution.

P4, N=152, Recruiting, Lee's Pharmaceutical Limited

P4, N=100, Active, not recruiting, Oslo University Hospital | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025

Our findings suggest that in the treatment group, necroptosis was triggered by increased MLKL and RIPK1, key players in inflammation and cell death. After immunocytochemical evaluation, our findings suggest that, after the onset of inflammation, favipiravir may play a role in cell death by increasing necroptosis rather than apoptosis.

P3, N=20, Active, not recruiting, Dartmouth-Hitchcock Medical Center | Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Sep 2025

P2, N=35, Not yet recruiting, Centre hospitalier de l'Université de Montréal (CHUM) | Initiation date: Sep 2023 --> Dec 2023

The patient was treated with high-dose prednisone and mycophenolate mofetil (MMF) for targeted treatment of both dermatomyositis and FSGS, with subsequent improvement to partial remission in the first 6 months. To our knowledge, this is the first reported case of kidney involvement with amyopathic dermatomyositis. B. Tubuloreticular inclusion on Electron Microscopy

These symptoms responded well to a high dose of systemic steroid, but even upon receiving a high-dose intravenous immunoglobulin, the panniculitic lesions and pruritic erythema flared with tapering of steroid dose, further requiring tacrolimus and mycophenolate mofetil to achieve disease remission. To our knowledge, this is the third reported case of anti-SAE autoantibody-positive dermatomyositis with panniculitis. We aim to extend the understanding of the current limitation and further perspective in the clinical management of the extremely rare skin manifestation associated with dermatomyositis.

The neuroprotective effect of organic Se compounds, selenomethionine (SeMet) and Ebselen, was evaluated through cell viability tests, acetylcholinesterase and antioxidant enzyme activities, and detection of reactive oxygen species (ROS). Cell differentiation induced by RA and BDNF exposure was effective, showing characteristics of neuronal cells, and pointing to a promising model of AD. Ebselen showed a protective effect, but more studies are needed to identify the mechanism of action.

P4, N=418, Completed, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting --> Completed | Trial primary completion date: Jul 2022 --> Aug 2023

P2, N=24, Recruiting, Liverpool School of Tropical Medicine | Not yet recruiting --> Recruiting